Adaptimmune Therapeutics PLC (ADAP)

[jondoeuk]

Connective Tissue Oncology Society:

Presentation - Durable Responses in Patients with Synovial Sarcoma in the Phase 1 Trial of ADP-A2M4 (MAGE-A4) https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/description/CTOS_BVT_29Oct2020_FINAL_FINAL.pdf

The Synovial Sarcoma Subset Analysis of the Multi-Histology Phase I Trial of ADP-A2M4 (MAGE-A4) https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/description/Jill+Rogers+-+Van+Tine_CTOS_ADP-A2M4+SS_11Nov2019+%28clean%29.pdf

SITC:

Phase 1 Clinical Trial Evaluating the Safety of ADP-A2M10 S+PEAR T-Cells in Patients with MAGE-A10 Advanced Non-Small Cell Lung Cancer https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/description/Jillian+Rogers+-+NSCLC+eposter_G+Blumenschein+SITC+%28CLH07%29+FINAL+UPLOAD+copy.pdf

Phase 1 Clinical Trial Evaluating the Safety of ADP-A2M10+ SPEAR T-Cells in Patients with MAGE-A10 Head and Neck, Melanoma, or Urothelial Tumors https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/description/Jillian+Rogers+-+Triple+Tumor+eposter_D+Hong+SITC+%28CM07%29+FINAL+UPLOAD+copy.pdf

Inhibition of AKT Signaling During Expansion of TCR-Engineered T-Cells from Patient Leukocyte Material Generates SPEAR T-Cells with Enhanced Functional Potential In Vitro https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/description/Jillian+Rogers+-+DP005-20++SITC+2020+AKTi+eposter+CM07+copy.pdf

Initial Safety, Efficacy, and Product Attributes from the SURPASS Trial with ADP-A2M4CD8, a SPEAR T-Cell Therapy Incorporating an Affinity Optimized TCR Targeting MAGE-A4 and a CD8a Co-Receptor https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/description/Jillian+Rogers+-+SURPASS+eposter_SITC+2020_D+Hong+et+al+%28cm08%29+FINAL_UPLOAD+copy.pdf

Case Reports: Correlates of Response Following Adoptive Transfer of ADP-A2M4, Affinity-Enhanced T-Cells Targeting MAGE-A4 in Synovial Sarcoma https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/Jill+Rogers+-+DP004-19+SITC+2019+Case+Reports+Poster_FINAL.pdf

SPEARHEAD-1 Trial Design: A Phase 2, Single-Arm, Open-Label Clinical Trial of ADP-A2M4 SPEAR T-Cells in Patients with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/Jill+Rogers+-+DP004-19+SITC+2019+SPEARHEAD-1+Trial+Poster_FINAL.pdf

SURPASS Trial Design: A Phase 1 Dose Escalation Trial to Assess Safety and Efficacy of ADP-A2M4CD8 in HLA-A2+ Patients with MAGE-A4+ Tumors https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/Jill+Rogers+-+DP004-19+SITC+2019+Case+Reports+Poster_FINAL.pdf